- Home>
- Specialty Care>
- HIV/AIDS>
- Initial Therapy
Initial Therapy
Physician-authored summaries on the latest research on initial therapy, editorials on initial therapy, and perspectives on initial therapy - drawn from the top medical journals.
You searched for: initial therapy Items 1 to 20 of 56 results
Sort by:
- Relevance
- Date
-
Early Virologic Failure with Tenofovir/FTC + Nevirapine as Initial TherapyFree!
- April 14, 2008
- Paul E. Sax, MD
Investigators stopped a clinical study when three of seven patients receiving tenofovir/FTC + nevirapine experienced early virologic rebound; each had evidence of multiclass viral resistance.- Covering:
- Lapadula G et al., Clin Infect Dis 2008 Apr 1; 46:1127.
-
Efavirenz vs. Lopinavir/Ritonavir for Initial Therapy
- February 1, 2005
- Keith Henry, MD
In a small nonrandomized study, open-label treatment with efavirenz and lopinavir/ritonavir resulted in similar peak CD4 counts and rates of virologic suppression; the efavirenz group had a higher CD4 count and a lower rate of AIDS at baseline.- Covering:
- Manfredi R et al., AIDS 2004 Nov 19; 18:2331-3.
-
Can Lopinavir/Ritonavir Be Dosed Once-Daily in Initial Therapy?
- March 1, 2004
- Bruce Soloway, MD
A small study suggests that once-daily and twice-daily lopinavir/ritonavir administration produce comparable clinical outcomes in treatment-naive patients, although other questions about once-daily dosing remain unanswered.- Covering:
- Eron JJ et al., J Infect Dis 2004 Jan 15; 189:265-72.
-
Maraviroc in Treatment-Experienced and Treatment-Naive PatientsFree!
- September 10, 2007
- Charles B. Hicks, MD
Data presented at the 4th IAS Conference confirm the value of maraviroc for treatment-experienced patients, but its role in treatment-naive patients remains uncertain. -
Standard Triple-Drug Regimens Remain the Best for Initial TherapyFree!
- December 29, 2006
Efavirenz-based regimens appear to be particularly effective. -
NNRTIs More Durable Than PIs as Initial Therapy
- December 1, 2004
- Keith Henry, MD
In this prospective observational study, initial NNRTI-based combination therapy led to fewer regimen changes than did initial PI-based combination therapy.- Covering:
- Klein MB et al. , AIDS 2004 Sep 24; 18:1895-904.
-
Abacavir as Initial Therapy and as a Once-Daily Drug
- November 1, 2003
- Paul E. Sax, MD
Preliminary results from two industry-sponsored studies suggested that abacavir -- currently used most commonly in treatment-experienced patients -- could be used in combination with 3TC and efavirenz as part of an initial antiretroviral regimen. -
Metabolic Effects of PIs vs. NNRTIs
- March 26, 2007
- Graeme Moyle, MD
Five-year results from the FIRST trial suggest that the choice between a PI and an NNRTI in initial therapy does not play an important role in limb-fat loss.- Covering:
- Shlay JC et al., J Acquir Immune Defic Syndr 2007 Feb 22;:
-
Old Drugs, New Data
- September 14, 2005
- Charles B. Hicks, MD
Researchers at IAS reported on the benefits of once-daily tenofovir + FTC + efavirenz as initial therapy, described a new needle-free injection system for T-20, and announced the impending availability of lopinavir/ritonavir in tablet formulation. -
DHHS Treatment Guidelines Tweaked AgainFree!
- February 11, 2008
- Abigail Zuger, MD
Specific drug recommendations for initial antiretroviral therapy have changed in this latest set of guidelines.- Covering:
- Panel on Antiretroviral Guidelines for Adults and Adolescents., 2008 Jan 29;:
-
Revised Package Insert for AtazanavirFree!
- January 28, 2008
- Paul E. Sax, MD
The insert includes new information on administering the drug with acid-reducing therapies and on appropriate dosing in patients with renal failure. -
Top HIV/AIDS Stories of 2007Free!
- December 28, 2007
- Paul E. Sax, MD
A perspective on the year’s most important stories in HIV medicine -
A Role for Unboosted Atazanavir?
- May 25, 2007
- Paul E. Sax, MD
Patients on successful initial treatment with PI-based regimens tended to do better when the PI was switched to atazanavir.- Covering:
- Gatell J et al., Clin Infect Dis 2007 Jun 1; 44:1484-92.
-
Prevalence and Predictors of Triple-Class Drug Resistance
- May 7, 2007
- Helmut Albrecht, MD
The development of triple-class resistance is rare in patients who initiate antiretroviral therapy with a regimen that includes either a potent NNRTI or a boosted PI.- Covering:
- Napravnik S et al., AIDS 2007 Apr 23; 21:825-34.
-
Treatment Options for Antiretroviral-Naive PatientsFree!
- April 2, 2007
- Paul E. Sax, MD
The 14th Retrovirus Conference advanced our understanding of which antiretroviral regimens are best for treatment-naive patients. -
NNRTIs Best PIs . . . AgainFree!
- January 8, 2007
- Paul E. Sax, MD
In a large randomized trial of treatment-naive patients, the most virologically active strategy was two NRTIs plus an NNRTI; a triple-class strategy yielded greater toxicity but not greater efficacy.- Covering:
- MacArthur RD et al., Lancet 2006 Dec 16; 368:2125-35.
- Abgrall S., Lancet 2006 Dec 16; 368:2107-9.
-
Expanded HIV Treatment in Resource-Poor CountriesFree!
- December 29, 2006
Initial concerns that antiretroviral therapy would be less effective in resource-poor settings ― or that patients there would be less adherent ― appear to be unfounded. -
Top HIV/AIDS Stories of 2006Free!
- December 29, 2006
The ACC editors offer their perspective on the year’s most important stories in HIV medicine. -
Report from the XVI International AIDS ConferenceFree!
- September 18, 2006
Now that the dust has settled, the ACC physician-editors provide their perspectives on 10 important topics from the well-attended meeting in Toronto. -
Four Drugs Not Better Than Three for HIVFree!
- September 11, 2006
- Rajesh T. Gandhi, MD
In HIV-infected patients starting antiretroviral therapy, addition of abacavir to zidovudine, lamivudine, and efavirenz does not improve treatment results.- Covering:
- Gulick RM et al., JAMA 2006 Aug 16; 296:769-81.
You searched for: initial therapy Items 1 to 20 of 56 results